

February 11, 2025

The Manager –Listing
BSE Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring
Rotunda Building, P J Towers,
Dalal Street, Fort, Mumbai 400001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir/Ma'am,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has received a warning letter from BSE Limited ('BSE') on February 11, 2025.

The information pertaining to the said letter in terms of Regulation 30 of SEBI Listing Regulations, in the prescribed format, is given as **Annexure - 1**.

Further, the said letter received from BSE is enclosed as **Annexure – 2**.

Kindly take the above information on record.

Thanking You
For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

Annexure - 1

| Sl. No. | Particulars | Response |
|---------|--|---|
| 1. | Name of the Authority | BSE Limited |
| 2. | Nature and details of the action(s) taken, initiated or order(s) passed | Warning letter |
| 3. | Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority | February 11, 2025 |
| 4. | Details of the violation(s)/ contravention(s) committed or alleged to be committed | Quorum for the Audit Committee meeting held on May 27, 2024 not met under Regulation 18(2)(b) of the SEBI Listing Regulations |
| 5. | Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible | None |

LIST/COMP/RK/1607/2024-25

Date: February 11, 2025

To,
The Company Secretary/ / Compliance Officer
AstraZeneca Pharma India Ltd
Block N1, 12 Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore, Karnataka- 560045.

Subject: Warning letter under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("the Regulations").

Dear Sir/Madam,

This is with reference to the Corporate Governance Report submitted by AstraZeneca Pharma India Limited ('the Company') for quarter ended June 2024. Further, referring to Regulation 18(2)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 stating that:

"The quorum for Audit Committee meeting shall either be two members or one third of the members of the audit committee, whichever is greater, with at least two independent directors."

It was observed that the Company is in non-compliance with the provisions of Reg. 18(2)(b) of SEBI (LODR) Regulations, 2015 as only one Independent Director attended the Audit Committee meeting held on May 27, 2024.

The afore-mentioned non-compliance has been viewed seriously by the Exchange. You are hereby warned and advised to ensure compliance with all applicable provisions laid down by SEBI through its Regulations. Any such aberration in future would be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of the warning letter on the Stock Exchange(s) where it is listed. Additionally, the Company is advised to place before their Board of Directors, this warning letter and the corrective measures taken by the Company to avoid such lapses.

Yours faithfully,


Shyam Bhagirath
Manager
Listing Compliance


Rohan Kallan
Assistant Manager
Listing Compliance